Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed limited stage small cell lung cancer (SCLC) Completed first line combination treatment consisting of at least a 2 drug chemotherapy regimen (4 to 6 courses) and a chest radiotherapy regimen Must have achieved clinical response (complete or partial) with no evidence of progression or relapse PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: WBC greater than 3,000/mm^3 Platelet count greater than 100,000/mm^3 Hepatic: AST less than 1.5 times upper limit of normal No hepatitis B Renal: Not specified Other: No history of tuberculosis Purified Protein Derivative negative to at least 5 IU HIV negative No severe active infection No active infections requiring systemic antibiotics, antiviral, or antifungal treatments No serious unstable chronic illness No other prior malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or nonmelanomatous skin cancer No psychological, familial, sociological, or geographical condition that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy No prior therapy with mouse proteins No other concurrent immunotherapy before first disease progression Chemotherapy: See Disease Characteristics No concurrent chemotherapy before first disease progression Endocrine therapy: No concurrent systemic or chronic corticosteroids Radiotherapy: See Disease Characteristics No prior radiation to spleen No concurrent radiotherapy before first disease progression Surgery: No prior surgery for SCLC No prior splenectomy Other: At least 4 weeks since prior combination therapy No prior second line therapy for SCLC At least 4 weeks since other prior investigational agent No concurrent systemic antihistamines or nonsteroidal antiinflammatory drugs No concurrent immunosuppressant therapy before first disease progression